Company Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis.
Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis.
The company’s pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders.
In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera.
Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
| Country | United States |
| Founded | 2002 |
| IPO Date | Apr 12, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 368 |
| CEO | Mihael Polymeropoulos |
Contact Details
Address: 2200 Pennsylvania Avenue NW, Suite 300E Washington, District of Columbia 20037 United States | |
| Phone | 202 734 3400 |
| Website | vandapharma.com |
Stock Details
| Ticker Symbol | VNDA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001347178 |
| CUSIP Number | 921659108 |
| ISIN Number | US9216591084 |
| Employer ID | 03-0491827 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mihael H. Polymeropoulos M.D. | Founder, President, Chief Executive Officer and Chairman of The Board |
| Kevin Patrick Moran | Senior Vice President, Chief Financial Officer and Treasurer |
| Timothy Williams J.D. | Senior Vice President, General Counsel and Secretary |
| Joakim Wijkstrom | Senior Vice President and Chief Marketing Officer |
| Gunther Birznieks | Senior Vice President of Business Development |
| Scott L. Howell | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Jan 27, 2025 | 8-K | Current Report |
| Nov 14, 2024 | 144 | Filing |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |